Why the study?
Growing clinical experience with angiotensin II in cardiac surgery enables the development of initial therapeutic algorithms for distributive shock following extracorporeal circulation.
This position paper provides a structured therapeutic algorithm for the use of angiotensin II in treating distributive shock following extracorporeal circulation in cardiac surgery.
AT algorithms proposed for post-ECC distributive shock; leaves open need for prospective validation before adoption.
Angiotensin II (AT) is a potent vasoconstrictor and hypertensive drug that is registered for the treatment of severe hypotension in vasoplegic shock. Growing experience with the use of AT in cardiac surgery allows the first therapeutic algorithms to be created. This paper is a proposal for the use of AT in distributive shock after extracorporeal circulation.
No takes yet. Share an insight, caveat, or question.
Krzych et al. (2024) conducted a review in Distributive shock after extracorporeal circulation. Angiotensin II was evaluated. Angiotensin II is proposed as a second-line vasopressor for distributive shock after extracorporeal circulation when mean arterial pressure remains <65 mm Hg despite norepinephrine equivalent doses of 0.3 µg/kg/min.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: